Is rusfertide available outside clinical trials?

No. Rusfertide (PTG-300) is an investigational hepcidin mimetic currently in Phase 3 clinical trials. It has received FDA Breakthrough Therapy Designation for polycythemia vera, which may accelerate the regulatory review process, but it is not yet commercially available.

How does rusfertide work differently from current PV treatments?

Unlike phlebotomy (which mechanically removes blood) or hydroxyurea (which suppresses bone marrow proliferation), rusfertide mimics hepcidin to restrict iron availability for red blood cell production. This addresses the underlying mechanism of erythrocytosis without broad cytoreduction. PV patient communities view this as a more targeted and tolerable approach.

What did the VERIFY trial show?

The Phase 3 VERIFY trial demonstrated a 77% clinical response rate for hematocrit control without phlebotomy in PV patients. The treatment also improved PV-related symptoms including fatigue and pruritus. These results support regulatory submission and potential FDA approval.

Rusfertide: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Anecdotal ReportsBased on 15 community reports

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides →

✓Reviewed byEditorial Team

📅Updated February 16, 2026

Unverified

📌TL;DR

•1 community protocols documented
•Evidence level: Anecdotal Reports
•Based on 15 community reports
•1 stacking patterns reported

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

Aspect	Clinical Approach	Community Approach	Significance
Clinical Trial Only	Rusfertide is in Phase 3 clinical trials (VERIFY trial) for polycythemia vera. It is administered by weekly subcutaneous injection with dose individualized to maintain hematocrit below 45%.	Community discussion is primarily among PV patients following the treatment pipeline and those enrolled in clinical trials. Rusfertide is not available outside clinical trials.	high The PV patient community has shown significant interest in rusfertide as an alternative to phlebotomy and cytoreductive therapy, particularly given the high response rates in clinical trials.
Phlebotomy Reduction	The VERIFY trial showed 77% clinical response rate, with the primary endpoint being hematocrit control without the need for phlebotomy.	PV patients frequently discuss the burden of regular phlebotomy and express interest in treatments that could eliminate or reduce the need for blood draws. Community interest in rusfertide is driven primarily by the prospect of phlebotomy-free disease management.	moderate For PV patients, eliminating phlebotomy represents a significant improvement in quality of life and disease management burden.

Compare these community approaches with published research findings.

Community Protocols

VERIFY Phase 3 Trial Protocol

Niche

Route: Subcutaneous injection
Dose: 40-80 mg weekly (individualized based on response)
Frequency: Once weekly
Duration: 52 weeks (trial) with planned long-term extension

Phase 3 clinical trial protocol; not yet commercially available; FDA Breakthrough Therapy Designation

Stacking Patterns

Rusfertide + Standard PV Management

Niche

Rusfertide as add-on to existing PV management (with or without cytoreductive therapy) for improved hematocrit control; trial design allowed concurrent use of hydroxyurea

rusfertide

Check stack compatibility and review potential side effects before combining peptides.

Unlock community dosing protocols and stacking combos

See the exact doses, routes, and schedules 15+ self-experimenters report. Free with email.

150+ peptide profiles · 30+ comparisons · 18 research tools

Already subscribed?

Sources

MPN Research Foundation|Polycythemia vera treatment pipeline and rusfertide discussions(accessed 2026-02-16)
Reddit r/mpn|Polycythemia vera treatment discussions including rusfertide(accessed 2026-02-16)
Protagonist Therapeutics|Rusfertide clinical development updates(accessed 2026-02-16)

Community Evidence Overview#

This page presents aggregated community discussions and context for rusfertide (PTG-300). This is not clinical evidence and should not be used as medical guidance.

Rusfertide is an investigational hepcidin mimetic peptide in Phase 3 clinical trials for polycythemia vera. Community discussion is concentrated among PV patients following the treatment pipeline and those interested in alternatives to phlebotomy.

PV Patient Community Interest#

The polycythemia vera patient community has shown significant interest in rusfertide due to its potential to eliminate or reduce the need for therapeutic phlebotomy. Key community discussion themes include:

Phlebotomy burden: PV patients frequently discuss the inconvenience, discomfort, and iron deficiency associated with regular phlebotomy
Treatment pipeline: The PV community actively tracks clinical trial progress for new therapies
Breakthrough Therapy Designation: FDA Breakthrough Therapy status is viewed positively as a signal of potential accelerated approval
Mechanism of action: Interest in the hepcidin mimetic approach as a more targeted alternative to cytoreductive therapy

Current Status#

Rusfertide is not yet commercially available. PV patients interested in access should discuss clinical trial participation with their hematologist. The MPN Research Foundation and Protagonist Therapeutics provide updates on trial enrollment and regulatory progress.

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.